Redeye provides a comment on Scandinavian ChemoTech's recently announced collaboration with a global...
EMB Mission Bound (”EMB” eller ”Bolaget”), f.d. Embark Group, har publicerat bolagets delårsrapport ...
Obducat genomför en företrädesemission 20 mars - 3 april om 50 MSEK till teckningskurs 0,75 SEK, vil...
Acquiring consulting company BlakYaks at 10.7x EV/EBITA Seems to be a good growing and highly profit...
Redeye comments on Paxman’s directed issue to institutional investors, raising SEK123.
Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of M...
Redeye comments on the positive phase I data from the study conducted by Leaderna in China.
Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 19 mars 2025 att Bolaget har erhållit ytter...
Redeye comments on the reverse split and new conditions of TO12.
This morning GomSpace announced a directed share issue of SEK200m to its largest shareholder the Har...
Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar eval...
Redsense avslutar 2024 starkt med sitt första helår av vinst.
EBITA margin above 6% No more than 1.5x Net debt/EBITDA RTM Dividend at ~30% of net profit Ambitiou...
Redeye comments on Paxman’s takeover offer to Dignitana, valued at approximately SEK153m, representi...
Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.
Det fjärde kvartalet kom in under våra förväntningar både vad gäller omsättning och marginaler.
Sprint Bioscience has secured 73.9% of a proposed SEK 31.
Q4 EBIT and guidance pre-announced, portfolio return better Conference call failed to ease three key...
Redeye endorses today’s news that Acarix was named the 2025 Digital Innovation Winner by the Global ...
